Sandoz has signed an agreement to acquire the US biosimilar ranibizumab CIMERLI® from Coherus BioSciences.
Sandoz has signed an agreement to acquire the US biosimilar ranibizumab CIMERLI® (ranibizumab-eqrn) from Coherus BioSciences, for an upfront cash purchase payment of USD 170 million. This agreement is inclusive of a biologics license application, product inventory, ophthalmology sales and…